Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO).
Wislez M, Mazieres J, Lavole A, Zalcman G, Carre O, Egenod T, Caliandro R, Dubos-Arvis C, Jeannin G, Molinier O, Massiani MA, Langlais A, Morin F, Le Pimpec Barthes F, Brouchet L, Assouad J, Milleron B, Damotte D, Antoine M, Westeel V.
Wislez M, et al. Among authors: caliandro r.
J Immunother Cancer. 2022 Oct;10(10):e005636. doi: 10.1136/jitc-2022-005636.
J Immunother Cancer. 2022.
PMID: 36270733
Free PMC article.